These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8299382)

  • 1. Suppression of induced inflammation in man.
    Kerscher MJ
    Curr Probl Dermatol; 1993; 21():97-106. PubMed ID: 8299382
    [No Abstract]   [Full Text] [Related]  

  • 2. The UV erythema test as a model to investigate the anti-inflammatory potency of topical preparations--reevaluation and optimization of the method.
    Jocher A; Kessler S; Hornstein S; Schulte Mönting J; Schempp CM
    Skin Pharmacol Physiol; 2005; 18(5):234-40. PubMed ID: 16015022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
    Korting HC
    Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
    [No Abstract]   [Full Text] [Related]  

  • 4. Side effects of topical glucocorticoids.
    Mills CM; Marks R
    Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
    [No Abstract]   [Full Text] [Related]  

  • 5. Investigation of the anti-inflammatory potential of Aloe vera gel (97.5%) in the ultraviolet erythema test.
    Reuter J; Jocher A; Stump J; Grossjohann B; Franke G; Schempp CM
    Skin Pharmacol Physiol; 2008; 21(2):106-10. PubMed ID: 18253066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of glucocorticoid-specific epidermal alterations using skin surface microscopy.
    Schulz H; Nietsch KH; Höhler T
    Curr Probl Dermatol; 1993; 21():132-9. PubMed ID: 8299366
    [No Abstract]   [Full Text] [Related]  

  • 7. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
    Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
    Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
    Kerscher MJ; Korting HC
    Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity and area increase of UVB-induced erythema: two variables used for studies of the influence of topically applied drugs.
    Juhlin L; Shroot B
    Acta Derm Venereol; 1993 Aug; 73(4):273-5. PubMed ID: 7904100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial comparing hydrocortisone 17-butyrate to betamethasone 17-valerate in a series of patients with eczematous skin diseases.
    Thormann J; Brodthagen H
    Dermatologica; 1976; 152 Suppl 1():209-14. PubMed ID: 782955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local tolerability of topically applied methylprednisolone aceponate.
    Kecskés A; Jahn P; Lange L
    J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
    Korting HC
    Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasoconstrictor and the anti-inflammatory effects of 7 corticosteroids.
    Crijns MB; Nater JP; van Oostveen F; van der Valk PG
    Contact Dermatitis; 1984 Aug; 11(2):108-11. PubMed ID: 6488765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UVB erythema inhibited by topically applied substances.
    Väänänen A; Hannuksela M
    Acta Derm Venereol; 1989; 69(1):12-7. PubMed ID: 2563602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of ultraviolet erythema by topical corticosteroids.
    Sukanto H; Nater JP; Bleumink E
    Dermatologica; 1980; 161(2):84-8. PubMed ID: 7398988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of hydrocortisone valerate 0.2% ointment.
    Sefton J; Loder JS; Kyriakopoulos AA
    Clin Ther; 1984; 6(3):282-93. PubMed ID: 6373007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betamethasone valerate in corticosteroid-dependent asthmatics. The integrity of the hypothalamic pituitary adrenal axis.
    Roscoe P; Choo-Kang YF; Horne NW
    Br J Dis Chest; 1975 Oct; 69(0):240-6. PubMed ID: 1106745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of 0.25% and 0.05% desoxymethasone, 0.1% betamethasone valerate and 1% hydrocortisone creams in the treatment of eczema.
    Ashton RE; Catterall M; Morley N; Fairris G; Joseph DN
    J Int Med Res; 1987; 15(3):160-6. PubMed ID: 3301455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the base on the results of clinical trials with topical corticosteroids.
    Vollum DI; Sparkes CG
    Dermatologica; 1979; 158(4):293-8. PubMed ID: 372027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.